News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Pairing targeted drugs for breast and lung cancer could overcome treatment resistance
Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows.
ICR alumni return to inspire the next generation at the 2019 Student Conference
At The Institute of Cancer Research’s annual Student Conference, our PhD students had the opportunity to meet with ICR alumni and find out more about their career journeys.
Immunotherapy could work against bowel cancers resistant to important targeted treatment
Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.
ICR recognises next generation of cancer researchers
A new generation of cancer researchers took to the stage at London’s Guildhall this week as The Institute of Cancer Research, London, held its annual awards ceremony.
ICR honours campaigning parents and convergence scientist with honorary degrees
The ICR has awarded the founders of the children’s cancer charity Christopher’s Smile and a world-leading expert in convergence science with honorary degrees at this year’s awards ceremony.
Response to gene-targeted drugs depends on cancer type
Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.
Two-in-one drug combining Herceptin with chemotherapy keeps women’s breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.
Cancer-killing virus boosts immunotherapy in hard-to-treat cancer
Combining a cancer-killing virus with immunotherapy could effectively treat advanced cancers that affect the limbs, a new study reveals.
ICR in top five in the world for academic influence and commercial impact
The ICR has ranked among the top higher education institutions in the world for the impact of its research academically and commercially.
ICR appoints Dr Adrian Cottrell, GSK Vice President, as Chief Information Officer
The Institute of Cancer Research, London, today announces the appointment of a leading international expert in research and development IT at GlaxoSmithKline (GSK), to lead its information and communication technologies.
Cancer's last note – Royal Philharmonic Orchestra create 'unfinished symphony' to support new cancer centre
The Institute of Cancer Research, London and the Royal Philharmonic Orchestra create an ‘unfinished symphony’ for cancer research – to raise funds to complete a revolutionary new research building
ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer
A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports.
